Mark Edelstein

411 total citations
27 papers, 321 citations indexed

About

Mark Edelstein is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Mark Edelstein has authored 27 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Hematology. Recurrent topics in Mark Edelstein's work include Acute Lymphoblastic Leukemia research (4 papers), DNA Repair Mechanisms (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Mark Edelstein is often cited by papers focused on Acute Lymphoblastic Leukemia research (4 papers), DNA Repair Mechanisms (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Mark Edelstein collaborates with scholars based in United States, Netherlands and Germany. Mark Edelstein's co-authors include Teresa J. Vietti, Fred Valeriote, Frederick A. Valeriote, L. M. van Putten, Heinz H. Fiebig, Thomas H. Corbett, Michael Bischoff, Laurence H. Baker, E. A. de Bruijn and Uwe Reichert and has published in prestigious journals such as Blood, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

Mark Edelstein

26 papers receiving 289 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Edelstein United States 9 147 88 59 55 55 27 321
M.J. Tilby United Kingdom 8 175 1.2× 96 1.1× 26 0.4× 33 0.6× 40 0.7× 9 332
Tamer Zeren United States 9 127 0.9× 108 1.2× 77 1.3× 44 0.8× 27 0.5× 16 343
Manon Verwijs-Janssen Netherlands 11 281 1.9× 143 1.6× 64 1.1× 27 0.5× 79 1.4× 13 424
Marlena Walls United States 8 202 1.4× 84 1.0× 29 0.5× 26 0.5× 33 0.6× 11 312
Frida Schain Sweden 12 124 0.8× 58 0.7× 22 0.4× 77 1.4× 35 0.6× 27 340
Fay Young United States 8 314 2.1× 169 1.9× 23 0.4× 98 1.8× 78 1.4× 9 534
Rebecca E. Parker United States 12 179 1.2× 70 0.8× 20 0.3× 70 1.3× 27 0.5× 23 398
Sueo Mukumoto Japan 8 310 2.1× 120 1.4× 25 0.4× 26 0.5× 54 1.0× 9 495
Murray Yule United States 12 335 2.3× 211 2.4× 26 0.4× 77 1.4× 49 0.9× 31 575
R.G. Fish United Kingdom 10 162 1.1× 61 0.7× 12 0.2× 11 0.2× 61 1.1× 26 346

Countries citing papers authored by Mark Edelstein

Since Specialization
Citations

This map shows the geographic impact of Mark Edelstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Edelstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Edelstein more than expected).

Fields of papers citing papers by Mark Edelstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Edelstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Edelstein. The network helps show where Mark Edelstein may publish in the future.

Co-authorship network of co-authors of Mark Edelstein

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Edelstein. A scholar is included among the top collaborators of Mark Edelstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Edelstein. Mark Edelstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Yuxiang, Marcia I. Dawson, Ramzi M. Mohammad, et al.. (2002). Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood. 100(8). 2917–2925. 47 indexed citations
2.
Edelstein, Mark, et al.. (1998). HEMORRHAGIC ASCITES DUE TO CONGESTIVE HEART FAILURE. The American Journal of Gastroenterology. 93(7). 1176–1177. 1 indexed citations
3.
Edelstein, Mark, Thomas H. Corbett, & Fred Valeriote. (1998). In Vitro Screening Model for the Detection of Agents Active Against Myelogenous Leukemia. Cancer Investigation. 16(5). 303–308. 2 indexed citations
4.
Highley, Martin, D. Schrijvers, A.T. van Oosterom, et al.. (1997). Activated oxazaphosphorines are transported predominantly by erythrocytes. Annals of Oncology. 8(11). 1139–1144. 24 indexed citations
5.
Valeriote, Frederick A., Thomas H. Corbett, Mark Edelstein, & Laurence H. Baker. (1996). New In Vitro Screening Model for the Discovery of Antileukemic Anticancer Agents. Cancer Investigation. 14(2). 124–141. 21 indexed citations
6.
Nakeff, Alexander, Mark KuKuruga, Joseph Media, Frederick A. Valeriote, & Mark Edelstein. (1996). Quantitative measurements of the efficacy of new anti-cancer agents on fresh human AML cells by using multivariate flow analysis.. PubMed. 1(6). 361–7. 1 indexed citations
7.
Edelstein, Mark, et al.. (1990). A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. Investigational New Drugs. 8(S1). S83–S86. 3 indexed citations
8.
Edelstein, Mark. (1989). Infused L-Histidinol and Cisplatin: Schedule, Specificity, and Proliferation Dependence. JNCI Journal of the National Cancer Institute. 81(4). 298–301. 5 indexed citations
9.
Valeriote, Frederick A., et al.. (1989). In vivo DNA cross-linking by cyclophosphamide: comparison of human chronic lymphatic leukemia cells with mouse L1210 leukemia and normal bone marrow cells.. PubMed. 49(13). 3452–6. 23 indexed citations
10.
Edelstein, Mark & Lance K. Heilbrun. (1988). Specificity, schedule, and proliferation dependence of infused L-histidinol after 5-fluorouracil in mice.. PubMed. 48(6). 1470–5. 4 indexed citations
11.
Edelstein, Mark, et al.. (1984). Improvements and limitations of the subrenal capsule assay for determining tumour sensitivity to cytostatic drugs. European Journal of Cancer and Clinical Oncology. 20(12). 1549–1556. 21 indexed citations
12.
Eliason, James F. & Mark Edelstein. (1983). In vivo studies on the regeneration kinetics of haemopoietic spleen colony-forming cells from long-term bone marrow cultures.. PubMed. 16(4). 375–83. 1 indexed citations
13.
Edelstein, Mark, et al.. (1983). Comparison between macroscopic and microscopic evaluation of tumour responsiveness using the subrenal capsule assay. European Journal of Cancer and Clinical Oncology. 19(7). 995–1009. 36 indexed citations
14.
Edelstein, Mark, et al.. (1983). A phase I clinical tolerance study of rDNA alpha2 human interferon in patients with non-reticuloendothelial system malignancies. European Journal of Cancer and Clinical Oncology. 19(7). 891–894. 8 indexed citations
15.
Lelieveld, P., J.H. Mulder, Mark Edelstein, & L. M. van Putten. (1980). Cell Kinetic Factors, Single Drugs and Combination. Recent results in cancer research. 74. 279–284. 1 indexed citations
16.
Edelstein, Mark, Fred Valeriote, & TJ Vietti. (1978). Influence of continuous infusion of cytosine arabinoside on sequencing with daunorubicin in L1210 leukemia.. PubMed. 62(4). 547–8. 2 indexed citations
17.
Mulder, J.H., et al.. (1978). Synergism and schedule dependent cytotoxicity of cyclophosphamide and CCNU in experimental cancer chemotherapy. European Journal of Cancer (1965). 14(5). 537–542. 7 indexed citations
18.
Edelstein, Mark & Fred Valeriote. (1977). Retention of 1-β-d-arabinofuranosylcytosine in vitro—. Biochemical Pharmacology. 26(6). 477–480. 2 indexed citations
19.
Edelstein, Mark, Fred Valeriote, & Teresa J. Vietti. (1977). Cellular Quantitation of In Vivo Effects of 1-β-d-Arabinofuranosylcytosine on Leukemia L12102. JNCI Journal of the National Cancer Institute. 58(4). 941–947. 21 indexed citations
20.
Edelstein, Mark, Teresa J. Vietti, & Frederick A. Valeriote. (1975). The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.. PubMed. 35(6). 1555–8. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M.J. Tilby Breakdown of academic impact, for papers by Tamer Zeren Breakdown of academic impact, for papers by Manon Verwijs-Janssen Breakdown of academic impact, for papers by Marlena Walls Breakdown of academic impact, for papers by Frida Schain Breakdown of academic impact, for papers by Fay Young Breakdown of academic impact, for papers by Rebecca E. Parker Breakdown of academic impact, for papers by Sueo Mukumoto Breakdown of academic impact, for papers by Murray Yule Breakdown of academic impact, for papers by R.G. Fish
Rankless by CCL
2026